239.83

0.18% 0.43

After Hours: 238.03 -1.80 -0.75%

Jazz Pharmaceuticals Plc (JAZZ)

Overview News Price History Option Chain Financials Discussions Forecast

Jazz Pharmaceuticals Plc stock is traded at $239.83, with a volume of 549.78K. It is up +0.18% in the last 24 hours and up +18.49% over the past month. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Previous Close:

$239.40

Open:

$242.93

24h Volume:

549.78K

Relative Volume:

0.55

Market Cap:

$15.05B

Revenue:

$4.44B

Net Income/Loss:

$29.49M

P/E Ratio:

-13,034.24

EPS:

-0.0184

Net Cash Flow:

$1.19B

1W Performance:

+4.83%

1M Performance:

+18.49%

6M Performance:

+35.55%

1Y Performance:

+122.45%

1-Day Range:

$239.20

$243.32

1-Week Range:

$227.64

$243.32

52-Week Range:

$105.00

$243.32

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name

Jazz Pharmaceuticals Plc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

353-1-634-7800

Address

FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN

Employee

2,890

Twitter

@jazzpharma

Next Earnings Date

2026-05-05

Latest SEC Filings

JAZZ's Discussions on Twitter

Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JAZZ Jazz Pharmaceuticals Plc	239.83	15.02B	4.44B	29.49M	1.19B	-0.0184
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Resumed	Raymond James	Outperform
Feb-27-26	Initiated	Barclays	Overweight
Nov-24-25	Downgrade	UBS	Buy → Neutral
Jul-15-25	Initiated	Deutsche Bank	Buy
Mar-07-25	Upgrade	UBS	Neutral → Buy
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-05-24	Initiated	Goldman	Buy
Jan-03-24	Initiated	Robert W. Baird	Outperform
Nov-27-23	Downgrade	UBS	Buy → Neutral
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight
Dec-09-22	Upgrade	Goldman	Neutral → Buy
Jun-14-22	Initiated	UBS	Buy
Apr-06-22	Downgrade	Goldman	Buy → Neutral
Nov-19-21	Resumed	Goldman	Buy
Oct-07-21	Resumed	Jefferies	Buy
Oct-05-21	Initiated	Citigroup	Buy
Sep-23-21	Initiated	Needham	Buy
May-19-21	Resumed	JP Morgan	Overweight
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight
Jan-29-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-16-20	Initiated	UBS	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Oct-09-20	Reiterated	H.C. Wainwright	Buy
Sep-14-20	Downgrade	Goldman	Neutral → Sell
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-06-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-28-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jul-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-06-20	Initiated	Jefferies	Buy
Mar-12-20	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-08-20	Initiated	Goldman	Neutral
Aug-21-19	Downgrade	Piper Jaffray	Overweight → Neutral
Jun-11-19	Initiated	Barclays	Overweight
Mar-20-19	Initiated	SunTrust	Buy
Dec-14-18	Initiated	Wolfe Research	Peer Perform
Nov-08-18	Reiterated	B. Riley FBR	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jul-11-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-23-18	Reiterated	H.C. Wainwright	Neutral
Mar-19-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight

View All

Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News

May 25, 2026

Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com

May 25, 2026